The Case for Daily Dosing — and What the Evidence Does and Doesn't Support

The dosing-interval argument is a pharmacokinetic one, and it deserves to be stated as such. If a drug's effects track its concentration, and concentration varies across a dosing interval, then a shorter interval produces less variation. That reasoning is coherent, and the dose-response evidence supports its premise: fat-free mass, strength, hemoglobin and IGF-I all correlate with testosterone concentration.[1] What does not yet exist is the trial randomising men to the same weekly total given daily versus weekly and measuring how they feel.

This page sets out both halves honestly, because the gap between them is where most of the overclaiming happens.

What the concentration data actually show

The clearest window comes from the dose-response study, which reported mean nadir concentrations — the low point of the interval — for five weekly injection doses: 253, 306, 542, 1,345 and 2,370 ng/dL.[1]

The word "nadir" is the interesting part. Reporting a nadir at all confirms what everyone assumes about longer-interval dosing: concentration is not flat across the week, so a single number does not describe the whole interval. The dose determines where the low point sits.

And because the study found effects correlating with concentration rather than with dose alone,[1] variation across an interval is at least mechanistically capable of producing variation in effect.

What that argument cannot claim

Three limits, stated plainly.

Mechanism is not outcome. A smoother concentration curve is a pharmacokinetic property. Whether it produces better symptom control, better adherence or fewer side effects is an empirical question that needs an outcome trial, and the head-to-head trial has not been run.

One randomised trial comes close, and it is not a clean test. A 24-week study randomised 66 hypogonadal men to a nightly transdermal system or 200 mg testosterone enanthate IM every two weeks. The injection arm ran supraphysiological for several days after each dose; the transdermal arm stayed within physiological range. Abnormal hematocrit elevations followed the profile — 43.8% versus 15.4% — as did subnormal LH, 31% versus 0%.[6]

But it varied route, product and interval together, so it cannot isolate interval. And critically, both arms maintained sexual function and mood at prior levels.[6] The smoother profile showed up in blood counts, not in how men felt.

The larger trials did not test this at all. TRAVERSE used a topical gel throughout — it was not designed to compare schedules.[2] Its sub-studies tell us what testosterone does versus placebo, not what one schedule does versus another.[3]

Time-course varies by preparation, unquantified. The standard time-course review attributes the variation it documents in part to "pharmacodynamics of the testosterone preparation" — an explicit statement that formulation matters, offered without a comparison table.[4]

What the guideline says about choosing an interval

It does not rank schedules. It suggests aiming at mid-normal testosterone concentrations with any of the approved formulations, taking into account patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden and cost.[5]

Pharmacokinetics is on that list — so the consideration is legitimate. So are four other things, including treatment burden and preference. A daily routine is more frequent but individually smaller in effort; a weekly one is rarer but more of an event. Which suits you is a real input, not a soft one, and compliance is among the four things the guideline asks clinicians to monitor.[5]

Where topical delivery sits in this

Topical administration is inherently a daily-interval approach, which is what puts it in this conversation at all. The published pharmacokinetic work on the transdermal spray platform Keen uses is set out in the published clinical evidence.

Two things stay true regardless of interval. Topical testosterone carries transfer precautions — an FDA boxed warning applies to gels for secondary exposure, and washing hands, letting the site dry and covering it are class requirements, not product-specific ones. See gel transfer risk. And the monitoring is the same: serum testosterone, hematocrit, symptoms, adverse effects, compliance and prostate cancer risk in the first year.[5]

Frequently asked questions

Is daily dosing better than weekly? Better at producing a steadier concentration — and in the one randomised comparison, that translated into fewer abnormal hematocrit elevations and less gonadotropin suppression, but no difference in reported mood or sexual function.[6] Also worth knowing: weekly subcutaneous dosing held levels stable in a small study,[7] so the swing is not intrinsic to injecting.

Why do men report feeling worse late in a weekly cycle? It is a common report with a plausible mechanism — nadir concentrations are real and dose-dependent.[1] The one randomised head-to-head that measured mood and sexual function found both maintained on the swinging profile and the smooth one alike.[6] The objective differences were real; the symptom difference was not found.

Does the interval change my monitoring? No. The guideline's monitoring plan is the same set of checks regardless of formulation.[5] See the 3-month panel.

Does a daily schedule mean a lower total dose? Not necessarily — the total is set by your target, which is mid-normal.[5] Interval describes how it is divided.

How to have the conversation

Ask about the interval as one of five considerations the guideline actually names, not as the deciding one. And be sceptical — including of anyone selling you a schedule — of any claim that presents a concentration curve as proof of how you will feel.

Keen connects you with a licensed clinical team for a telehealth consultation and lab review. If your testosterone is clinically low, treatment is Keen Testosterone Spray Rx — a once-daily topical spray powered by Hypospray® transdermal delivery.

Related reading: what "microdosing" actually means and how long TRT takes to work.

References

7 sources

1. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–E1181. doi:10.1152/ajpendo.2001.281.6.E1172 · PMID 11701431
2. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107–117. doi:10.1056/NEJMoa2215025 · PMID 37326322
3. Pencina KM, Travison TG, Cunningham GR, et al. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024;109(2):569–580. doi:10.1210/clinem/dgad484 · PMID 37589949
4. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–685. doi:10.1530/EJE-11-0221 · PMID 21753068
5. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
6. Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men. J Clin Endocrinol Metab. 1999;84(10):3469–3478. doi:10.1210/jcem.84.10.6078 · PMID 10522982
7. McFarland J, Craig W, Clarke NJ, et al. Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone. J Endocr Soc. 2017;1(8):1095–1103. doi:10.1210/js.2017-00148 · PMID 29264562